Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Saxagliptin add-on versus metformin uptitration in type 2 diabetes
2009-012775-10Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Jul 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Saxagliptin add-on to metformin 1500 mg/day with Metformin uptitration to maximum 2500 mg/day (2 arms). Primary endpoint: Absolute change from baseline in HbA1c at Week 24. Started Jul 2009; status: completed.
02
Drugs
saxagliptinmetformin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2009-012775-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-012775-10.